Dr. Anil K. Gupta Medicine Professional Corporation

Toronto, Ontario M9V 4B4

1 studies enrolling now · 17 studies all time

What they study most

Asthma, Body Weight, CKD, COVID-19, Cardiovascular Disease, Cytomegalovirus Infection, Diabetes Mellitus, Type 2, Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias, Influenza A, Lower Respiratory Tract Illness

Studies at this site

• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Recruiting now
• A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma — Completed
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 — Completed
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age — Stopped early
• A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — Completed
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications — Stopped early
• A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus — Completed
• A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection — Stopped early
• A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System — Completed
• A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) — Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes — Completed
• A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early